retatrutide obesity triple hormone receptor agonist Medscape | Retatrutide, Eli Lilly's first-in-class agonist, delivered meaningful weight loss at 80 weeks in all doses in the Triple–Hormone-Receptor Agonist Retatrutide for Obesity
Pay in 4 interest-free payments of $6.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4



























